SCHEMBL5758541

SCHEMBL5758541

Cc1ccc(C(N)=O)c(=O)n1-c1cccc(C(F)(F)F)c1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.59
NOTUM Q6P988 2/20 0.56
PLA2G10 O15496 1/20 0.51
CYP1A2 P05177 1/20 0.48
POLB P06746 1/20 0.46
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.45
GSR P00390 3/20 0.44
GAA P10253 1/20 0.43
RPS6KB1 P23443 1/20 0.43
AKT1 P31749 1/20 0.43
BRD9 Q9H8M2 1/20 0.42
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
TSHR P16473 1/20 0.41
ALKBH5 Q6P6C2 1/20 0.41
SYK P43405 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL561046 0.88 NOTUM (0.68) ELANENOTUMCYP1A2POLBMAPT
SCHEMBL560874 0.83 ELANE (0.57) ELANENOTUMCYP1A2MAPTGSR
SCHEMBL27624353 0.83 ELANE (0.52) ELANENOTUMPLA2G10CYP1A2POLB
SCHEMBL27716691 0.81 NOTUM (0.53) ELANENOTUMPLA2G10CYP1A2POLB
SCHEMBL5757500 0.81 ELANE (0.58) ELANENOTUMPLA2G10CYP1A2POLB
SCHEMBL561039 0.80 ELANE (0.65) ELANENOTUMCYP1A2POLBLMNA
SCHEMBL5759088 0.79 ELANE (0.64) ELANENOTUMCYP1A2POLBHPGD
SCHEMBL5757624 0.79 ELANE (0.64) ELANENOTUMCYP1A2POLBLMNA
SCHEMBL5755788 0.79 ELANE (0.79) ELANENOTUMPOLBLMNAMAPT
SCHEMBL5757787 0.79 ELANE (0.59) ELANENOTUMPOLBLMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250114376-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF AVALYN PHARMA INC. 2025-04-10 US disclosed
CN-101142189-A 2-pyridine derivatives as inhibitors of neutrophile elastase ASTRAZENECA AB (SE) 2008-03-12 CN disclosed
EP-1562902-B1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2006-05-03 EP disclosed
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase ASRAZENECA AB (SE) 2006-02-16 US disclosed
CN-1711243-A 2-pyridone derivatives as inhibitors of neutrophil elastase ASTRAZENECA AB (SE) 2005-12-21 CN disclosed
EP-1562902-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE AstraZeneca AB (SE) 2005-08-17 EP disclosed
WO-2004043924-A1 2-PYRIDONE DERIVATIVES AS INHIBITORS OF NEUTROPHILE ELASTASE ASTRAZENECA AB (SE) 2004-05-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060035938-A1 2-Pyridone derivatives as inhibitors of neutrophile elastase SERPINB1, ELANE, SERPINE1 ELANE 2/4885NOTUM 3748/4885PLA2G10 312/4885
US-20250114376-A1 AEROSOL PIRFENIDONE AND PYRIDONE ANALOG COMPOUNDS AND USES THEREOF PLPBP, PIR, PDXK ELANE 1574/4885NOTUM 4443/4885PLA2G10 761/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.